We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
Read MoreHide Full Article
Shares of Medivation, Inc. hit a 52-week high of $80.99 on Thursday, Sep 9.
Shares of the biopharmaceutical company have been up more than 20% ever since pharmaceutical giant Pfizer Inc. (PFE - Free Report) announced its intention to buy it.
On Aug 22, Pfizer and Medivation announced that they have entered into a definitive merger agreement, under which Pfizer will acquire Medivation for $81.50 per share in cash for a total enterprise value of about $14 billion.
How will Medivation Benefit?
We note that Medivation was the topic of acquisition talks for quite a while, with the company first receiving an offer from French drugmaker Sanofi (SNY - Free Report) . Sanofi had initially approached Medivation with an offer of $52.50 in cash, which was rejected by the company. Sanofi came back with a sweetened bid of $58.00 per share in cash, plus a Contingent Value Right (CVR) for talazoparib sales, representing a potential payment in 2022 of up to $3.00 per share.
Pfizer’s offer price of $81.50 to Medivation represents a huge premium on Sanofi’s last offer. The signing of the deal with Pfizer has assigned proper value to Xtandi and Medivation’s promising late-stage pipeline candidates, especially talazoparib, which should accelerate growth.
The cash nature deal is a huge boost for the stock as well as Medivation’s cash position, thereby delivering significant and immediate value to shareholders.
What about Pfizer?
The Medivation acquisition will strengthen Pfizer’s cancer franchise, which currently consists of products like Ibrance and Sutent. Pfizer is also working on strengthening its immuno-oncology pipeline and this buyout will be a strategic fit for the company.
With this takeover, Pfizer will add Medivation’s prostate cancer treatment, Xtandi, to its portfolio. Xtandi is currently being evaluated in several studies, including a couple of late-stage studies in non-metastatic prostate cancer, and another phase III study in hormone-sensitive prostate cancer. It is also in mid-stage development for the treatment of advanced breast cancer and hepatocellular carcinoma.
Moreover, Medivation’s pipeline candidate talazoparib, an orally-available PARP inhibitor, represents significant potential. Pfizer will also add pidilizumab to its pipeline with this acquisition. Pidilizumab is an immuno-oncology (IO) asset which is being developed for diffuse large B-cell lymphoma and other hematologic malignancies, and which could be combined with IO therapies in Pfizer’s portfolio.
Medivation carries a Zacks Rank #5 (Strong Sell). A better-ranked stock in the pharmaceutical sector is Anika Therapeutics Inc. (ANIK - Free Report) , which sports a Zacks Rank #1 (Strong Buy).
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
Shares of Medivation, Inc. hit a 52-week high of $80.99 on Thursday, Sep 9.
Shares of the biopharmaceutical company have been up more than 20% ever since pharmaceutical giant Pfizer Inc. (PFE - Free Report) announced its intention to buy it.
MEDIVATION INC Price
MEDIVATION INC Price | MEDIVATION INC Quote
The Deal
On Aug 22, Pfizer and Medivation announced that they have entered into a definitive merger agreement, under which Pfizer will acquire Medivation for $81.50 per share in cash for a total enterprise value of about $14 billion.
How will Medivation Benefit?
We note that Medivation was the topic of acquisition talks for quite a while, with the company first receiving an offer from French drugmaker Sanofi (SNY - Free Report) . Sanofi had initially approached Medivation with an offer of $52.50 in cash, which was rejected by the company. Sanofi came back with a sweetened bid of $58.00 per share in cash, plus a Contingent Value Right (CVR) for talazoparib sales, representing a potential payment in 2022 of up to $3.00 per share.
Pfizer’s offer price of $81.50 to Medivation represents a huge premium on Sanofi’s last offer. The signing of the deal with Pfizer has assigned proper value to Xtandi and Medivation’s promising late-stage pipeline candidates, especially talazoparib, which should accelerate growth.
The cash nature deal is a huge boost for the stock as well as Medivation’s cash position, thereby delivering significant and immediate value to shareholders.
What about Pfizer?
The Medivation acquisition will strengthen Pfizer’s cancer franchise, which currently consists of products like Ibrance and Sutent. Pfizer is also working on strengthening its immuno-oncology pipeline and this buyout will be a strategic fit for the company.
With this takeover, Pfizer will add Medivation’s prostate cancer treatment, Xtandi, to its portfolio. Xtandi is currently being evaluated in several studies, including a couple of late-stage studies in non-metastatic prostate cancer, and another phase III study in hormone-sensitive prostate cancer. It is also in mid-stage development for the treatment of advanced breast cancer and hepatocellular carcinoma.
Moreover, Medivation’s pipeline candidate talazoparib, an orally-available PARP inhibitor, represents significant potential. Pfizer will also add pidilizumab to its pipeline with this acquisition. Pidilizumab is an immuno-oncology (IO) asset which is being developed for diffuse large B-cell lymphoma and other hematologic malignancies, and which could be combined with IO therapies in Pfizer’s portfolio.
Medivation carries a Zacks Rank #5 (Strong Sell). A better-ranked stock in the pharmaceutical sector is Anika Therapeutics Inc. (ANIK - Free Report) , which sports a Zacks Rank #1 (Strong Buy).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>